Neoadjuvant Lenvatinib Plus Pembrolizumab in Resectable Merkel Cell Carcinoma
This is a single arm trial of participants with Merkel cell carcinoma receiving a combination of lenvatinib plus pembrolizumab.
- Assess the pathological complete response rate for resectable Merkel cell carcinoma treated with the combination of pembrolizumab and lenvatinib in the neoadjuvant setting.
- Assess the progression free survival of resectable Merkel cell carcinoma treated with neoadjuvant pembrolizumab and lenvatinib
Male/female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of Merkel cell carcinoma will be enrolled in this study. The clinical stage of the patient must be stage II, III, or IV at the time of enrollment
Have clinically or radiographically detectable disease that is felt by the treating physician to be amenable to complete surgical resection
Have provided archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated.
Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Be willing and able to perform home blood pressure monitoring
Have adequate organ function as defined by protocol
Male participants must agree to use contraception as detailed in Appendix 3 of this protocol during the treatment period and for at least 6 days after the last dose of study treatment and refrain from donating sperm during this period.
Female participants are eligible to participate is they are not pregnant, not breastfeeding, and at least one of the following childbearing potential as defined by protocol:
A. Not a woman of childbearing potential as defined in protocol OR
B. A woman of childbearing potential who agrees to follow the contraceptive guidance per protocol during the treatment period and for at least 30 days after the last dose of the study treatment.
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137)
Has receive prior therapy with a systemic anti-VEGFR inhibitor for oncologic purposes
Uncontrolled blood pressure in spite of an optimized regimen of antihypertensive medication
Significant cardiovascular impairment defined by protocol
Bleeding or thrombotic disorders or subjects at risk for severe hemorrhage
Participants having > 1+ proteinuria on urine dipstick testing unless a 24-hour urine collection for quantitative assessment indicates that the urine protein is > Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks [could consider shorter interval for kinase inhibitors or other short half-life drugs] prior to [randomization /allocation]
Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (> Has received a live vaccine within 30 days prior to the first dose of study drug
Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug
Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
Has known active CNS metastases and/or carcinomatous meningitis
Has severe hypersensitivity (>Grade 3) to pembrolizumab and/or any of its excipients
Has active autoimmune disease that has required systemic treatment in the past 2 years
Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis
Has an active infection requiring systemic therapy
Has a known history of HIV
Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C virus
Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator
Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment.
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub